Get the Stockscreener App
2.24
2.61%
-0.06
Artiva Biotherapeutics Inc stock is traded at $2.24, with a volume of 289.01K.
It is down -2.61% in the last 24 hours and down -61.84% over the past month.
Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205).
See More
Previous Close:
$2.30
Open:
$2.26
24h Volume:
289.01K
Relative Volume:
1.09
Market Cap:
$47.75M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+21.74%
1M Performance:
-61.84%
6M Performance:
-82.47%
1Y Performance:
+0.00%
1-Day Range:
$2.15
$2.27
1-Week Range:
$1.8001
$2.37
52-Week Range:
$1.78
$17.31
Artiva Biotherapeutics Inc Stock (ARTV) Company Profile
Name
Artiva Biotherapeutics Inc
Sector
Industry
Phone
(858) 267-4467
Address
5505 MOREHOUSE DRIVE, SAN DIEGO
Compare ARTV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARTV
Artiva Biotherapeutics Inc
|
2.24 | 47.75M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Artiva Biotherapeutics Inc Stock (ARTV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-30-24 | Initiated | H.C. Wainwright | Buy |
| Aug-13-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-13-24 | Initiated | Jefferies | Buy |
| Aug-13-24 | Initiated | Needham | Buy |
| Aug-13-24 | Initiated | TD Cowen | Buy |
| Aug-13-24 | Initiated | Wedbush | Outperform |
View All
Artiva Biotherapeutics Inc Stock (ARTV) Latest News
NK Cell Therapy Therapeutics Market Size in 7MM is expected - openPR.com
Norges Bank Buys New Stake in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) - Defense World
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
Artiva Biotherapeutics’ (ARTV) “Buy” Rating Reaffirmed at Needham & Company LLC - Defense World
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Receives Consensus Rating of “Buy” from Brokerages - Defense World
Promising Outlook for Artiva Biotherapeutics Amid Strategic Manufacturing and Regulatory Support - TipRanks
Artiva Biotherapeutics names new Chief Medical Officer By Investing.com - Investing.com South Africa
Artiva Biotherapeutics Names New Chief Medical Officer - marketscreener.com
Artiva Biotherapeutics names new Chief Medical Officer - Investing.com Australia
Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical Officer - GlobeNewswire
Artiva Biotherapeutics (ARTV) – Investment Analysts’ Recent Ratings Changes - Defense World
Artiva Biotherapeutics Reports 2024 Financial Results - TipRanks
Artiva To Report Data From Phase I Trial Of AlloNK For Autoimmune Disease In H1 2025 - RTTNews
Artiva Biotherapeutics’ SWOT analysis: NK cell therapy stock faces pivotal year - Investing.com Canada
Artiva Biotherapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference - The Manila Times
Artiva Biotherapeutics’ SWOT analysis: NK cell therapy stock faces pivotal year By Investing.com - Investing.com South Africa
What is Wedbush’s Forecast for ARTV Q1 Earnings? - Defense World
HC Wainwright Issues Positive Forecast for ARTV Earnings - Defense World
Brokers Issue Forecasts for ARTV Q1 Earnings - Defense World
Artiva Biotherapeutics (NASDAQ:ARTV) Earns “Buy” Rating from HC Wainwright - Defense World
Cantor Fitzgerald Issues Negative Outlook for ARTV Earnings - Defense World
Artiva Biotherapeutics: Strong Buy Rating Backed by Promising Pipeline and Financial Stability - TipRanks
Artiva Biotherapeutics stock rises following analyst optimism By Investing.com - Investing.com South Africa
Artiva Biotherapeutics stock rises following analyst optimism - Investing.com
Artiva Biotherapeutics (NASDAQ:ARTV) Price Target Cut to $20.00 by Analysts at Cantor Fitzgerald - Defense World
Artiva Biotherapeutics’ (ARTV) “Outperform” Rating Reaffirmed at Wedbush - Defense World
NK Cell Therapy Pipeline 2025: Key Developments, Emerging - openPR.com
Goldman Sachs To Rally Around 8%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
Artiva Biotherapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights - GlobeNewswire
Artiva Biotherapeutics Reports Full Year 2024 Results and Updates on AlloNK® Autoimmune Program with Key Leadership Strengthening - Nasdaq
Artiva Biotherapeutics Inc. (ARTV) reports earnings - qz.com
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Contineum Therapeutics Announces Appointment of Diego Miralles, M.D. to Its Board of Directors - Business Wire
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World
Allogeneic CAR-T Cell Patent Landscape and Forecast Report - GlobeNewswire
Allogeneic CAR-T Cell Patent Landscape and Forecast Report 2024-2032, Profiles of Artiva Biotherapeutics, Poseida Therapeutics, Nanjing Beiheng Biological Technology, NantCell, GC Cell, BMS, Compugen - Yahoo Finance
Rhumbline Advisers Has $130,000 Position in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) - Defense World
Artiva Biotherapeutics (ARTV) Expected to Announce Earnings on Tuesday - Defense World
My Favorite "Magnificent Seven" Stock Just Joined the Quantum Computing Revolution (Hint: It's Not Nvidia) - The Globe and Mail
Nk Cell Therapy Pipeline 2024: FDA Updates, Therapy - openPR
Autodesk Designs Value for Investors: Uptrend Set to Continue - The Globe and Mail
NK Cell Therapy Market on Track for Exponential Growth Amid Rising Pipeline Developments | DelveInsight - GlobeNewswire Inc.
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat
Artiva Biotherapeutics to Participate in the TD Cowen 45th Annual Health Care Conference - GlobeNewswire
Financial Comparison: Compugen (NASDAQ:CGEN) & Artiva Biotherapeutics (NASDAQ:ARTV) - Defense World
Artiva Leverages Unmodified NK Cells To Challenge CAR-T Paradigm - Citeline News & Insights
Artiva Biotherapeutics Inc Stock (ARTV) Financials Data
There is no financial data for Artiva Biotherapeutics Inc (ARTV). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
2.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):